Uppsala, June 16, 2020. Dicot AB announces that the company has launched an English version of the website www.dicot.se, a step forward to reach the international market.
"Dicot wants to position itself as an international company in the area of men's sexual dysfunction. For the future development of our drug candidate, we want to work more internationally as our long-term goal is to establish Libiguin® as a global product against erectile dysfunction and premature ejaculation. " says Göran Beijer CEO at Dicot.
For further information, please contact:
Göran Beijer, CEO
Tel: +46 70-663 60 09
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 900 shareholders. For more information see www.dicot.se.